Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Scientists discover new kind of small-cell lung cancer

Researchers have discovered a new kind of small-cell lung cancer. The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease.

26 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Researchers discover new method to predict chance of cancer treatment success

Doctors are increasingly fighting cancer by stimulating patients' immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success.

12 Jun 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

HKBU researchers develop metal based probes for imaging dopamine receptors in living cells

A team led by Dr Edmond Ma Dik-lung, Associate Professor of the Department of Chemistry of Hong Kong Baptist University has developed the world's first iridium(III)-based probes for imaging dopamine receptors in living cells.

16 May 2018

Cleveland Clinic researcher wins NCI grant to delve into cancer genetics and radiation effectiveness

Can the genetic makeup of their cancers predict how patients with lung cancer will respond to radiation therapy? And can this information be used to advance a genetically guided strategy for patients with these tumors? Cleveland Clinic researcher and radiation oncologist Mohamed Abazeed, M.D., Ph.D., has been awarded a $2 million grant from the National Cancer Institute (NCI) to delve into those and other related questions.

15 May 2018

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck's anti-PD-1 therapy, KEYTRUDA®, along with chemotherapy.

8 May 2018

Study identifies new biomarker for early lung cancer diagnosis

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer.

8 May 2018

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).

8 May 2018

Slight changes in patient's position during radiotherapy may impact survival chances

Very small differences in the way a patient lies during radiotherapy treatment for lung or oesophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference.

23 Apr 2018

UT Southwestern researchers identify 170 potential therapeutic targets for lung cancer

After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

20 Apr 2018

Study challenges use of whole-brain radiation for small-cell lung cancer patients with brain metastases

Lung cancer often metastasizes to the brain. Historically, brain metastases have been treated with whole-brain radiation therapy.

17 Apr 2018

Anti-PD-1 treatment reduces tumor size and post-surgical relapse of lung cancer

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients.

16 Apr 2018

Targeting metabolism of key nutrients could be effective in treating squamous cell carcinoma

Researchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung.

12 Apr 2018

Nanotechnology-based treatment approach shown to be effective in mouse models of lung cancer

The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors.

11 Apr 2018

New class of drug holds potential to help patients with treatment-resistant cancers

Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.

10 Apr 2018

Finding new drug target for common form of lung cancer

Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the superoxide dismutase 1 (SOD1) enzyme providing support that it could serve as a therapeutic target in the most common type of lung cancer.

10 Apr 2018

FDA approves first treatment to reduce risk of NSCLC progression

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

18 Feb 2018

Small Cell Lung Cancer News and Research

Scientists discover new kind of small-cell lung cancer

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Researchers discover new method to predict chance of cancer treatment success

Price check on drug ads: Would revealing costs help patients control spending?

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

HKBU researchers develop metal based probes for imaging dopamine receptors in living cells

Cleveland Clinic researcher wins NCI grant to delve into cancer genetics and radiation effectiveness

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Study identifies new biomarker for early lung cancer diagnosis

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

Slight changes in patient's position during radiotherapy may impact survival chances

UT Southwestern researchers identify 170 potential therapeutic targets for lung cancer

Study challenges use of whole-brain radiation for small-cell lung cancer patients with brain metastases

Anti-PD-1 treatment reduces tumor size and post-surgical relapse of lung cancer

Targeting metabolism of key nutrients could be effective in treating squamous cell carcinoma

Nanotechnology-based treatment approach shown to be effective in mouse models of lung cancer

New class of drug holds potential to help patients with treatment-resistant cancers

Finding new drug target for common form of lung cancer

FDA approves first treatment to reduce risk of NSCLC progression

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News